Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares traveled higher Monday after climbing 14% on Friday. Lixte Biotech, earlier during the month, announced a $4.19-million registered direct offering.
This week, the company is taking part in the virtual 33rd Annual Roth Conference, being .
A webcast of Lixte’s investor presentation by Founder and Chief Executive Officer John S. Kovach, M.D. will be available on demand at the event website and at Lixte’s website under Investor Information: News & Events .
During the corporate presentation and in one-on-one and small group investor meetings, Dr. Kovach will discuss the Company’s proprietary clinical stage compound LB-100, a first in-class protein phosphatase (PP2A) inhibitor that increases the anti-tumor activity of standard chemotherapy, radiotherapy, and immunotherapy without increasing toxicity. LB-100 is initially being evaluated in three clinical treatment studies (phase 1b/2 for Myelodysplastic Syndromes,
Advanced Soft Tissue Sarcoma, and Small Cell Lung Cancer and in a phase 0 (human pharmacodynamic/pharmacokinetic study) in recurrent gliomas. LB-100 is also being tested for potential benefit in a rodent model of Angelman Syndrome, a severe neurodevelopmental disorder. There are no direct competitors of LB-100 known to Lixte in the clinic at present.
Lixte is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases.
LIXT shares collected 16 cents, or 3.6%, to $4.53.
